Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Free Report

White Paper_2017_State of China Life Science

State of China Life Science - 2017H1

Over $10B invested in last 18 months! Download free report on life science investment in China.

Medicago Licenses China Rights for Flu Vaccine to Phillip Morris Co.

publication date: Sep 26, 2012
View a Printer Friendly version of this page, allowing you to print the page.
Medicago, a Canadian vaccines company, has out-licensed China rights to its pandemic and seasonal flu vaccines to Philip Morris Products, the cigarette maker, in a $12 million deal. PMP has owned a 40% stake in Medicago since 2008. In addition, Medicago signed an exclusive license for a portfolio of plant-based protein development technologies from PMP. The technology will allow Medicago to grow its vaccines on tobacco plants, a faster, less-expensive production method than the methods currently in use. More details...

Stock Symbol: (TSX: MDG)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China